MXCT MaxCyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MXCT

Price (delayed)

$1.19

Market cap

$122.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.33

Enterprise value

$125.02M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 51
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 35

MaxCyte, the clinical-stage global cell-based therapies and life sciences company, uses its proprietary next-generation cell and gene therapies to revolutionise medical treatments and ultimately save lives. The Company’s premier cell ...

Highlights
The EPS has grown by 23% YoY and by 11% from the previous quarter
MXCT's net income is up by 20% YoY and by 9% QoQ
The equity has contracted by 17% YoY and by 5% from the previous quarter
The company's gross profit fell by 14% YoY and by 5% QoQ
Sector: Healthcare
Industry: Medical Devices
Website: https://maxcyte.com
Peers: ABT TMO DHR ISRG

Key stats

What are the main financial stats of MXCT

MXCT stock price

How has the MaxCyte stock price performed over time
Intraday
-4.03%
1 week
0.85%
1 month
-13.77%
1 year
-30.41%
YTD
-23.23%
QTD
-3.25%

Financial performance

How have MaxCyte's revenue and profit performed over time
Revenue
$31.05M
Gross profit
$24.6M
Operating income
-$41.79M
Net income
-$35.64M
Gross margin
79.2%
Net margin
-114.8%
The operating income has increased by 22% year-on-year and by 9% since the previous quarter
MXCT's net income is up by 20% YoY and by 9% QoQ
The company's gross profit fell by 14% YoY and by 5% QoQ
The revenue has declined by 13% year-on-year and by 3.8% since the previous quarter

Price vs fundamentals

How does MXCT's price correlate with its fundamentals

Growth

What is MaxCyte's growth rate over time

Valuation

What is MaxCyte stock price valuation
P/E
N/A
P/B
0.8
P/S
4.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.03
The EPS has grown by 23% YoY and by 11% from the previous quarter
MXCT's P/B is 58% below its 5-year quarterly average of 2.0 but 5% above its last 4 quarters average of 0.8
The equity has contracted by 17% YoY and by 5% from the previous quarter
MXCT's price to sales (P/S) is 64% less than its 5-year quarterly average of 11.8 but 4.1% more than its last 4 quarters average of 4.1
The revenue has declined by 13% year-on-year and by 3.8% since the previous quarter

Efficiency

How efficient is MaxCyte business performance
The ROIC has increased by 10% YoY and by 5% from the previous quarter
The ROS has grown by 8% YoY and by 5% from the previous quarter
The ROA has grown by 6% YoY and by 4.8% from the previous quarter
The return on equity is up by 5% year-on-year and by 4.5% since the previous quarter

Dividends

What is MXCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MXCT.

Financial health

How did MaxCyte financials performed over time
MXCT's total assets is down by 16% year-on-year and by 5% since the previous quarter
MXCT's total liabilities is down by 11% YoY and by 2.5% QoQ
MXCT's debt is 89% less than its equity
The equity has contracted by 17% YoY and by 5% from the previous quarter
MaxCyte's debt to equity has increased by 10% from the previous quarter and by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.